Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 34
---
 plans approved by stockholders     |     |                  | 64,948 | -1 |     | $                | 10.00 | -2 |     |               | 414,073 |
| Equity compensation plans not approved by stockholders |     |                  |      — |    |     |                  |     — |    |     |               |       — |
| Total                                                  |     |                  | 64,948 |    |     | $                | 10.00 |    |     |               | 414,073 |

| (1) | Includes 50 shares subject to outstanding stock options under                                                                     
 the 2016 Plan that were outstanding on December 31, 2023 (presented on an as-converted basis). No new awards may be granted under 
 the 2016 Plan.                                                                                                                    |

| (2) | Reflects the weighted-average exercise price of the $10.00 outstanding               
 stock options under the 2024 Plan and 2016 Plan, presented on an as-converted basis. |

17 On February 8, 2024, the stockholders approved the 2024 Plan and 2024 ESPP, with an initial reserve of 51,726 and 50,993 shares of common stock, respectively. The 2024 Plan and 2024 ESPP became effective on February 14, 2024 in connection with the closing of the Business Combination. At a special meeting of stockholders on April 30, 2024, the stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive stock options, by an additional 20,000 shares each. At a special meeting of stockholders on November 11, 2024, the stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive stock options, by an additional 208,454 shares each. As of January 8, 2025, no awards have been granted under the 2024 ESPP. No new awards may be granted under the 2016 Plan, but all outstanding awards under the 2016 Plan continue to be governed by their existing terms. The 2024 Plan has an evergreen provision that allows for an annual increase in the number of shares available for issuance under the 2024 Plan to be added on the first day of January, starting with